Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1E | P28566 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19995543 | 0.89 | HTR3A (0.46) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL12812338 | 0.83 | CHRNB2 (0.45) | HTR2ADRD2DRD3CHRNB2CHRNA7 | |
| SCHEMBL28296881 | 0.81 | HTR3A (0.42) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL16110833 | 0.79 | HTR2A (0.47) | HTR2ADRD2DRD3HTR6HTR2C | |
| SCHEMBL16455075 | 0.79 | HTR3A (0.47) | HTR2ACHRNB2CHRNA4HTR6HTR2C | |
| SCHEMBL10419750 | 0.78 | SLC6A2 (0.48) | HTR6HTR2CHTR1A | |
| Hydrochloric Acid SCHEMBL16446414 | 0.78 | HTR3A (0.46) | HTR2ACHRNB2CHRNA4HTR6HTR2C | |
| SCHEMBL27788973 | 0.77 | EPHX2 (0.40) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL1824314 | 0.77 | CHRNB2 (0.49) | CHRNB2CHRNA7CHRNA4HTR1A | |
| SCHEMBL2145272 | 0.77 | HTR6 (0.45) | HTR2ADRD2DRD3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101622258-B | Bicyclic oxomorpholine derivatives | EISAI R&D MAN CO LTD | 2012-06-13 | — | — | CN | claimed |
| CN-101312965-B | Morpholine type cinnamamide compound | EISAI R&D MAN CO LTD | 2011-07-20 | — | — | CN | claimed |
| CN-101910183-A | Preparation method of 4- (substituted phenyl) hexahydropyrido [2,1-C ] [1,4] oxazin-6-one | EISAI R&D MAN CO LTD | 2010-12-08 | — | — | CN | claimed |
| CN-101622258-A | Bicyclic oxomorpholine derivatives | EISAI R&D MAN CO LTD | 2010-01-06 | — | — | CN | claimed |
| CN-101472913-A | Prodrugs of cinnamide compounds | EISAI R&D MAN CO LTD (JP) | 2009-07-01 | — | — | CN | claimed |
| CN-101312965-A | Morpholine type cinnamamide compound | EISAI R&D MAN CO LTD (JP) | 2008-11-26 | — | — | CN | claimed |
| CN-101312972-A | Bicyclic cinnamide compound | EISAI R&D MAN CO LTD (JP) | 2008-11-26 | — | — | CN | claimed |
| CN-108721289-A | The purposes of benzo five-membered Azacyclyl piperidine derivative | 沈阳海王生物技术有限公司 | 2018-11-02 | — | — | CN | disclosed |
| US-9415047-B2 | Use of benzo five-membered nitrogen heterocyclic piperazine or piperidine derivatives | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2016-08-16 | — | — | US | disclosed |
| US-20150297586-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2015-10-22 | — | — | US | disclosed |
| EP-2924033-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | Liaoning Emmy Biological Pharmaceutical Co., Ltd (CN) | 2015-09-30 | — | — | EP | disclosed |
| CN-103830238-A | Use of benzo five-membered azaheterocyclyl piperidine derivatives | SHENYANG BEIEN PHARMACEUTICAL CO LTD | 2014-06-04 | — | — | CN | disclosed |
| CN-101312972-B | Bicyclic cinnamide compound | EISAI R&D MAN CO LTD | 2012-06-20 | — | — | CN | disclosed |
| CN-101312972-A | Bicyclic cinnamide compound | EISAI R&D MAN CO LTD (JP) | 2008-11-26 | — | — | CN | disclosed |
| CN-101312965-A | Morpholine type cinnamamide compound | EISAI R&D MAN CO LTD (JP) | 2008-11-26 | — | — | CN | disclosed |
| EP-0641320-B1 | SUBSTITUTED (S)-3-PHENYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINE AUTORECEPTOR ANTAGONISTS | UPJOHN CO (US) | 2001-05-30 | — | — | EP | disclosed |
| US-5594024-A | ANTIDEPRESSANTS; TREATMENT OF NARCOLEPSY, SCHIZOPHRENIA, DRUG ABUSE | THE UPJOHN COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| US-5462947-A | Nervous system disorders | THE UPJOHN COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0641320-A1 | NEW CENTRALLY ACTING SUBSTITUTED PHENYLAZACYCLOALKANES | PHARMACIA & UPJOHN COMPANY (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1992018475-A2 | SUBSTITUTED PHENYLAZACYCLOALKANES AS CNS AGENTS | THE UPJOHN COMPANY (US) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297586-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | P2RX5, TBXA2R, CYP3A5 | HTR2A 353/4885DRD2 445/4885DRD3 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.